Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

USA ...
Amazon Smile https://smile.amazon.com/ (bookmark)
choose MEBO RESEARCH INC
0.5% to MEBO on your purchases
(no extra cost to you)

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, June 12, 2017

The People behind the P&G TMA reducing supplement

Readers have been aware since 2015 that a trimethylamine reducing therapy has been on the cards. Here is some background (and guesswork) to the 'therapy' (speculated to be a supplement).

The 2 organisations involved  :
Cleveland Clinic (Innovations)
Procter & Gamble

Cleveland Clinic :
Has a long history of being a pioneer in heart disease research and treatment.

Dr Stanley Hazen (lab) :
Dr Stanley Hazen is one of the world's leading Heart Disease doctor's and researcher.

In 2011 his lab (Hazen et al) put forward a paper saying that Trimethylamine-n-oxide (TMAO) may be a strong causal factor for developing Heart Disease.pubmed ).
One obvious potential therapy was to stop gut microbes altering the likes of choline into TMA. One possible way to do this would be to interfere with the choline-TMA metabolism.
This seems to be what the patented product will do.
The lab has released many TMAO-CVD papers since 2011.
It seems most of the papers are have Dr Tang as lead researcher.
In this case the end product will probably come under the Cleveland Clinic INNOVATIONS dept. Or Cleveland Heartlab.

Procter & Gamble :
P&G is one of the biggest manufacturer and brand for household products, including some nutrition products.

It seems Cleveland ( Innovations ) have teamed up with P&G probably mostly under a licence agreement whereby P&G are the sellers of the product.

P&G Nutrition products :
A guess is that the TMA-inhibiting product will be sold as part of the P&G Nutrition range.
Perhaps as part of the 'Meta' range.
P&G Nutrition online shop
P&G current heart health product

Product patent (current version Dec 2016) : link

Inventor names on the patent :
Garcia-garcia, Jose Carlos (Cincinnati, OH, US)
Hazen, Stanley Leon (Pepper Pike, OH, US)
Wos, John August (Mason, OH, US)

Garcia-garcia, Jose Carlos.
Principal Scientist at Procter & Gamble

Hazen, Stanley Leon

Wos, John August
Principal Scientist at Procter & Gamble

When will we hear the latest news ?
Probably in a press release. Until they are ready, they will keep all info secret.
One idea is to follow Cleveland Innovations on Twitter.
But it will likely be major news when it is available.

Aug 2015 Press Release

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment